We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+15.04%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$221M
AUM Growth
-$21.6M
Cap. Flow
-$49.7M
Cap. Flow %
-22.47%
Top 10 Hldgs %
93.3%
Holding
38
New
7
Increased
5
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$1.94M
2
FENC icon
Fennec Pharmaceuticals
FENC
+$915K
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$781K
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$718K
5
WHWK
Whitehawk Therapeutics
WHWK
+$641K

Top Sells

Rank Stock Value
1
ARNC
Arconic Corporation
ARNC
+$18.7M
2
CHRD icon
Chord Energy
CHRD
+$15.8M
3
PDCE
PDC Energy, Inc.
PDCE
+$8.8M
4
CIVI
Civitas Resources
CIVI
+$4.44M
5
DRRX
DURECT Corp
DRRX
+$4.19M

Sector Composition

Rank Sector Weight
1 Technology 28.23%
2 Healthcare 11.32%
3 Energy 8.1%
4 Consumer Discretionary 1.95%
5 Materials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMTC icon
1
CALL
Semtech
SMTC
$12.2B
$63.6M 28.76%
+2,500,000
New +$54M
SMTC icon
2
Semtech
SMTC
$12.2B
$62.4M 28.22%
2,452,855
– –
MRNS
3
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$24.5M 11.08%
2,257,521
-362,575
-14% -$3.1M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$22.2M 10.02%
50,000
-100,000
-67% -$42M
CHRD icon
5
Chord Energy
CHRD
$7.86B
$15.7M 7.12%
102,403
-109,000
-52% -$15.8M
ARDX icon
6
Ardelyx
ARDX
$1.25B
$5.18M 2.34%
1,526,667
-510,000
-25% -$2.09M
BFI
7
DELISTED
BurgerFi International, Inc. Common Stock
BFI
$4.31M 1.95%
2,745,938
– –
MCRB icon
8
Seres Therapeutics
MCRB
$49.5M
$3.31M 1.5%
34,590
+4,750
+16% +$517K
DRRX
9
DELISTED
DURECT Corp
DRRX
$2.98M 1.35%
601,664
-826,642
-58% -$4.19M
BATL icon
10
Battalion Oil
BATL
$34.6M
$2.17M 0.98%
380,891
– –
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$4.83B
$1.84M 0.83%
130,691
+17,151
+15% +$230K
BLUE
12
DELISTED
bluebird bio
BLUE
$1.75M 0.79%
+26,563
New +$1.94M
MIST icon
13
Milestone Pharmaceuticals
MIST
$146M
$1.28M 0.58%
450,207
+25,000
+6% +$94.3K
ACRS icon
14
Aclaris Therapeutics
ACRS
$747M
$1.14M 0.52%
109,898
– –
TSVT
15
DELISTED
2seventy bio
TSVT
$1.13M 0.51%
111,667
-58,333
-34% -$618K
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$1.09M 0.49%
99,425
– –
INSM icon
17
Insmed
INSM
$23.1B
$1.06M 0.48%
50,335
– –
FENC icon
18
Fennec Pharmaceuticals
FENC
$356M
$971K 0.44%
+110,000
New +$915K
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$761K 0.34%
+7,400
New +$781K
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.84B
$722K 0.33%
+34,500
New +$718K
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$6.86B
$698K 0.32%
27,000
-70,000
-72% -$1.86M
WHWK
22
Whitehawk Therapeutics
WHWK
$187M
$564K 0.25%
+82,423
New +$641K
MRSN
23
CALL
DELISTED
Mersana Therapeutics
MRSN
$480K 0.22%
+5,840
New +$854K
ORGN
24
DELISTED
Origin Materials
ORGN
$426K 0.19%
3,333
– –
HARP
25
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$324K 0.15%
45,651
+28,723
+170% +$199K
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Lion Point Capital held 38 positions worth $221M, down 8.9% from $243M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Lion Point Capital withdrew a net $49.7M in Q2 2023, closing 8 positions and reducing 8 holdings. Its most notable exit was Arconic Corporation, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 24% a quarter earlier, followed by Healthcare and Energy.

Against the trend, Lion Point Capital opened a new position in bluebird bio worth $1.75M.

  • Lion Point Capital's largest Q2 2023 buy was bluebird bio: 26,563 shares worth $1.75M.
  • Lion Point Capital added most to Seres Therapeutics in Q2 2023, an estimated $517K increase.
  • Lion Point Capital's biggest Q2 2023 reduction was Chord Energy, cutting an estimated $15.8M.
  • Lion Point Capital fully exited Arconic Corporation in Q2 2023, selling an estimated $18.7M.
  • Lion Point Capital's ten largest holdings make up 93% of its $221M portfolio in Q2 2023.
  • Lion Point Capital opened 7 new positions and closed 8 in Q2 2023.
  • Lion Point Capital's portfolio value fell 8.9% quarter-over-quarter to $221M.

Based on Lion Point Capital's 13F filing for Q2 2023, filed 14 Aug 2023.